Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 402Rectal Neoplasms 151Colonic Neoplasms 148Pancreatic Neoplasms 111Stomach Neoplasms 106Neoplasm Metastasis 87Neoplasms 74Esophageal Neoplasms 59Small Cell Lung Carcinoma 44Neuroblastoma 42Lung Neoplasms 42Glioblastoma 38Carcinoma, Non-Small-Cell Lung 37Brain Neoplasms 33Esophageal Squamous Cell Carcinoma 32Unspecified Adult Solid Tumor, Protocol Specific 31Glioma 31Breast Neoplasms 28Central Nervous System Neoplasms 27Adenocarcinoma Of Esophagus 27Sarcoma 26Gliosarcoma 22Astrocytoma 22Rhabdomyosarcoma 21Sarcoma, Ewing 18Adenocarcinoma 18Gastrointestinal Neoplasms 17Oligodendroglioma 16Recurrence 13Medulloblastoma 13

Interventions

Gemcitabine 3130-nm albumin-bound paclitaxel 2sintilimab 1nimotuzumab 1avelumab 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Hydroxychloroquine 1Fluorouracil 1Capecitabine 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pancreatic Cancer Resectable × Irinotecan × Clear all
NCT07155629 2025-09-04

LEFT-PANC

Helsinki University Central Hospital

Phase 3 Not yet recruiting
381 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡